Printer Friendly

NeoPharm Sets Conference Call and Webcast for First Quarter Corporate Results.

WAUKEGAN, Ill. -- NeoPharm, Inc. (Nasdaq:NEOL) today announced the date and time for its regularly-scheduled quarterly conference call to discuss corporate developments and financial highlights for the first quarter ended March 31, 2006.

The conference call will be held on:
Friday, May 5, 2006 at 11:00 a.m. Eastern/8:00 a.m. Pacific
 -----------------------------------------------------------
 Domestic: 800-688-0836, passcode 45361215
 International: 617-614-4072, passcode 45361215

Audio replays will be available through May 12, 2006.
Domestic: 888-286-8010, passcode 61152573
International: 617-801-6888, passcode 61152573


The live call and replay will also be available via webcast at www.neopharm.com.

NeoPharm's Commitment to Oncology

NeoPharm employees share a common goal: bringing hope to cancer patients and their families through the research and development of new cancer drugs and therapies. The Company's oncology portfolio is built on two novel, proprietary platforms: a tumor-targeting platform, and the NeoLipid(R) Liposomal Drug Delivery platform. Through its research and clinical studies, as well as its work with physicians, scientists, and advocacy groups, NeoPharm is helping to enhance the lives of cancer patients.

About NeoPharm, Inc.

NeoPharm, Inc., based in Waukegan, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. Additional information, including ongoing clinical trials, can be obtained by visiting NeoPharm's Web site at www.neopharm.com.

Forward Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's drug development program, including, but not limited to clinical trials including cintredekin besudotox, future patient survival in the Company's ongoing Phase I/II studies and PRECISE trial, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in financing, development, testing, obtaining regulatory approval, production and marketing of the Company's drug and non-drug compounds, including, but not limited to, cintredekin besudotox, uncertainty regarding the availability of third party production capacity, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug and non-drug compounds, including, but not limited to, cintredekin besudotox, that could slow or prevent products coming to market, uncertainty regarding the Company's ability to market its drug and non-drug products, including, but not limited to, cintredekin besudotox, directly or through independent distributors, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, cintredekin besudotox, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including its annual reports on Form 10-K and quarterly reports on Forms 10-Q. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Apr 27, 2006
Words:551
Previous Article:Capital Campaign for Helen DeVos Children's Hospital Announced.
Next Article:Secured Digital Awarded $6.5 Million Contact for Security Installation.
Topics:


Related Articles
NeoPharm Announces Fourth Quarter Conference Call.
NeoPharm Announces First Quarter 2001 Conference Call.
NeoPharm Sets Conference Call and Webcast for Second Quarter Results.
NeoPharm Sets Conference Call and Webcast for Third Quarter Results.
NeoPharm Sets Conference Call and Webcast for Fourth Quarter and Fiscal Year End 2003 Results.
NeoPharm Sets Conference Call and Webcast for Third Quarter 2004 Results.
NeoPharm Sets Conference Call and Webcast for First Quarter 2005 Results.
NeoPharm Sets Conference Call and Webcast for Second Quarter 2005 Corporate Results.
NeoPharm Sets Conference Call and Webcast for Third Quarter 2005 Corporate Results.
NEOPHARM Sets Conference Call and Webcast for Second Quarter Corporate Results.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters